Shares of Exponent (EXPO) plunged 5.72% in pre-market trading on Friday following the release of its first-quarter 2025 earnings report and a subsequent price target cut by Truist Securities. The engineering and scientific consulting firm faced headwinds as it navigated through a challenging macroeconomic environment.

Exponent's Q1 2025 results fell short of expectations, with total revenue remaining flat at $145.5 million compared to the same period last year. More concerning was the decrease in net income to $26.7 million, or $0.52 per diluted share, down from $30.1 million or $0.59 per diluted share in Q1 2024. The company's EBITDA also declined by 6% to $37.5 million, with a margin of 27.3% of net revenues.

Adding to investor concerns, Exponent's management provided a cautious outlook for the second quarter, expecting utilization rates to decline due to holiday impacts and market uncertainties. The company also highlighted ongoing macroeconomic uncertainty, leading some clients to delay proactive work and impacting revenue growth. In response to these challenges, Truist Securities lowered its price target for Exponent from $120 to $100, further pressuring the stock. Despite these short-term hurdles, Exponent remains focused on strategic hiring in high-demand areas and leveraging its strong presence in reactive services, which are less impacted by economic cycles, to position itself for long-term sustainable growth.